{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:11:18Z","timestamp":1769155878480,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Microfibrillar-associated protein (MFAP4), initially identified as an extracellular matrix protein, has been demonstrated in multiple human disorders, but it is yet to be discovered following acute coronary syndrome (ACS) in clinical practice. Therefore, this study aimed to investigate the relationship between circulating MFAP4 levels and coronary stenosis in ACS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed the study in 148 ACS subjects, including 75 ST-segment elevation myocardial infarction (STEMI), 27 non-ST-segment elevation myocardial infarction (non-STEMI) and 46 unstable angina (UA). Clinical variables were collected and Gensini and Syntax stenosis scoring systems were applied to assess the severity of coronary stenosis. Kaplan\u2013Meier and logistic regression analysis were used to analyze the relationship between MFAP4 and the severity of coronary stenosis or ACS outcomes. Spearman analysis was used to describe the correlation between MFAP4 and clinical parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Circulating MFAP4 levels were significantly decreased in the STEMI group (0.008\u00a0ng\/ml) compared with the non-STEMI group (0.014\u00a0ng\/ml) and UA group (0.019\u00a0ng\/ml) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). After adjusting for confounding factors, we found that MFAP4 was an independent risk factor for STEMI (odds ratio\u2009=\u20090.395, 95% CI 0.174\u20130.895, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). MFAP4 level was negatively correlated with Gensini score and Syntax score (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u00a00.311 and \u2212\u00a00.211, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and 0.01, respectively). Based on the MFAP4 level of 0.117\u00a0ng\/ml, ACS patients were divided into two groups: the low-MFAP4 group (&lt;\u20090.117\u00a0ng\/ml, <jats:italic>n<\/jats:italic>\u2009=\u200960) and the high-MFAP4 group (\u2265\u20090.117\u00a0ng\/ml, <jats:italic>n<\/jats:italic>\u2009=\u200988). After the median follow-up of 165\u00a0days, Kaplan\u2013Meier survival analysis revealed that the MACE-free rate was significantly lower in ACS patients with lower MFAP4 levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.009).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MFAP4 has a potential as a biomarker for the degree of coronary stenosis in ACS. Confirmation of observations in larger cohorts and longer follow-up periods is warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01002-z","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T04:23:50Z","timestamp":1674015830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Declined plasma microfibrillar-associated protein 4 levels in acute coronary syndrome"],"prefix":"10.1186","volume":"28","author":[{"given":"Chunming","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanshu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongsheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pixiong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"6","key":"1002_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/FJC.0000000000000914","volume":"76","author":"Q Wang","year":"2020","unstructured":"Wang Q, Liang C. Role of lipid-lowering therapy in low-density lipoprotein cholesterol goal attainment: focus on patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2020;76(6):658\u201370.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"1002_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/ATVBAHA.115.306672","volume":"36","author":"A Schlosser","year":"2016","unstructured":"Schlosser A, Pilecki B, Hemstra LE, Kejling K, Kristmannsdottir GB, Wulf-Johansson H, Moeller JB, Fuchtbauer EM, Nielsen O, Kirketerp-Moller K, Dubey LK, Hansen PB, Stubbe J, Wrede C, Hegermann J, Ochs M, Rathkolb B, Schrewe A, Bekeredjian R, Wolf E, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Lindholt JS, Holmskov U, Sorensen GL. MFAP4 promotes vascular smooth muscle migration, proliferation and accelerates neointima formation. Arterioscler Thromb Vasc Biol. 2016;36(1):122\u201333.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1002_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082243","volume":"8","author":"H Wulf-Johansson","year":"2013","unstructured":"Wulf-Johansson H, Lock Johansson S, Schlosser A, Trommelholt Holm A, Rasmussen LM, Mickley H, Diederichsen AC, Munkholm H, Poulsen TS, Tornoe I, Nielsen V, Marcussen N, Vestbo J, Saekmose SG, Holmskov U, Sorensen GL. Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. PLoS ONE. 2013;8(12): e82243.","journal-title":"PLoS ONE"},{"issue":"1","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jcp.29893","volume":"236","author":"S Zhu","year":"2021","unstructured":"Zhu S, Ye L, Bennett S, Xu H, He D, Xu J. Molecular structure and function of microfibrillar-associated proteins in skeletal and metabolic disorders and cancers. J Cell Physiol. 2021;236(1):41\u20138.","journal-title":"J Cell Physiol"},{"key":"1002_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab124","author":"H Wang","year":"2021","unstructured":"Wang H, Liu M, Wang X, Shuai W, Fu H. MFAP4 deletion attenuates the progression of angiotensin II-induced atrial fibrosis and atrial fibrillation. Europace. 2021. https:\/\/doi.org\/10.1093\/europace\/euab124.","journal-title":"Europace"},{"issue":"6","key":"1002_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1161\/CIRCRESAHA.120.317146","volume":"128","author":"LE Dorn","year":"2021","unstructured":"Dorn LE, Lawrence W, Petrosino JM, Xu X, Hund TJ, Whitson BA, Stratton MS, Janssen PML, Mohler PJ, Schlosser A, Sorensen GL, Accornero F. Microfibrillar-associated protein 4 regulates stress-induced cardiac remodeling. Circ Res. 2021;128(6):723\u201337.","journal-title":"Circ Res"},{"issue":"17","key":"1002_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015307","volume":"9","author":"HB Wang","year":"2020","unstructured":"Wang HB, Yang J, Shuai W, Yang J, Liu LB, Xu M, Tang QZ. Deletion of microfibrillar-associated protein 4 attenuates left ventricular remodeling and dysfunction in heart failure. J Am Heart Assoc. 2020;9(17): e015307.","journal-title":"J Am Heart Assoc"},{"key":"1002_CR8","doi-asserted-by":"publisher","first-page":"117727192110163","DOI":"10.1177\/11772719211016359","volume":"16","author":"SG Saekmose","year":"2021","unstructured":"Saekmose SG, Holst R, Lottenburger T, Ytting H, Nielsen HJ, Junker P, Schlosser A, Sorensen GL. Circadian, week-to-week, and physical exercise-induced variation of serum microfibrillar-associated protein 4. Biomark Insights. 2021;16:11772719211016360.","journal-title":"Biomark Insights"},{"issue":"12","key":"1002_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082383","volume":"8","author":"SG Saekmose","year":"2013","unstructured":"Saekmose SG, Schlosser A, Holst R, Johansson SL, Wulf-Johansson H, Tornoe I, Vestbo J, Kyvik KO, Barington T, Holmskov U, Sorensen GL. Enzyme-linked immunosorbent assay characterization of basal variation and heritability of systemic microfibrillar-associated protein 4. PLoS ONE. 2013;8(12): e82383.","journal-title":"PLoS ONE"},{"issue":"4","key":"1002_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/hmg\/4.4.589","volume":"4","author":"Z Zhao","year":"1995","unstructured":"Zhao Z, Lee C, Jiralerspong S, Juyal R, Lu F, Baldini A, Greenberg F, Caskey C, Patel PJ. The gene for a human microfibril-associated glycoprotein is commonly deleted in Smith-Magenis syndrome patients. Hum Mol Genet. 1995;4(4):589\u201397.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1002_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1074\/jbc.M115.681775","volume":"291","author":"B Pilecki","year":"2016","unstructured":"Pilecki B, Holm AT, Schlosser A, Moeller JB, Wohl AP, Zuk AV, Heumuller SE, Wallis R, Moestrup SK, Sengle G, Holmskov U, Sorensen GL. Characterization of microfibrillar-associated protein 4 (MFAP4) as a tropoelastin- and fibrillin-binding protein involved in elastic fiber formation. J Biol Chem. 2016;291(3):1103\u201314.","journal-title":"J Biol Chem"},{"issue":"45","key":"1002_CR12","doi-asserted-by":"publisher","first-page":"32234","DOI":"10.1074\/jbc.274.45.32234","volume":"274","author":"M Lausen","year":"1999","unstructured":"Lausen M, Lynch N, Schlosser A, Tornoe I, Saekmose S, Teisner B, Willis A, Crouch E, Schwaeble W, Holmskov UJ. Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D. J Biol Chem. 1999;274(45):32234\u201340.","journal-title":"J Biol Chem"},{"issue":"11","key":"1002_CR13","doi-asserted-by":"publisher","first-page":"L1114","DOI":"10.1152\/ajplung.00351.2014","volume":"308","author":"AT Holm","year":"2015","unstructured":"Holm AT, Wulf-Johansson H, Hvidsten S, Jorgensen PT, Schlosser A, Pilecki B, Ormhoj M, Moeller JB, Johannsen C, Baun C, Andersen T, Schneider JP, Hegermann J, Ochs M, Gotz AA, Schulz H, de Angelis MH, Vestbo J, Holmskov U, Sorensen GL. Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. Am J Physiol Lung Cell Mol Physiol. 2015;308(11):L1114\u201324.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"1002_CR14","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2217\/epi-2018-0080","volume":"11","author":"J Yang","year":"2019","unstructured":"Yang J, Song H, Chen L, Cao K, Zhang Y, Li Y, Hao X. Integrated analysis of microfibrillar-associated proteins reveals MFAP4 as a novel biomarker in human cancers. Epigenomics. 2019;11(1):1635\u201351.","journal-title":"Epigenomics"},{"issue":"2","key":"1002_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7150\/jca.28127","volume":"10","author":"H Zhao","year":"2019","unstructured":"Zhao H, Sun Q, Li L, Zhou J, Zhang C, Hu T, Zhou X, Zhang L, Wang B, Li B, Zhu T, Li HJ. High expression levels of AGGF1 and MFAP4 predict primary platinum-based chemoresistance and are associated with adverse prognosis in patients with serous ovarian cancer. J Cancer. 2019;10(2):397\u2013407.","journal-title":"J Cancer"},{"issue":"5","key":"1002_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/15476286.2015.1023495","volume":"12","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Ma X, Sung D, Li M, Kosti A, Lin G, Chen Y, Pertsemlidis A, Hsiao T, Du LJ. microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol. 2015;12(5):538\u201354.","journal-title":"RNA Biol"},{"issue":"7","key":"1002_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/liv.14491","volume":"40","author":"BS Madsen","year":"2020","unstructured":"Madsen BS, Thiele M, Detlefsen S, Sorensen MD, Kjaergaard M, Moller LS, Rasmussen DN, Schlosser A, Holmskov U, Trebicka J, Sorensen GL, Krag A, GALAXY consortium. Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. Liver Int. 2020;40(7):1701\u201312.","journal-title":"Liver Int"},{"issue":"1","key":"1002_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12967-018-1523-6","volume":"16","author":"LE Hemstra","year":"2018","unstructured":"Hemstra LE, Schlosser A, Lindholt JS, Sorensen GL. Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease. J Transl Med. 2018;16(1):159.","journal-title":"J Transl Med"},{"issue":"11","key":"1002_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.18565\/cardio.2014.11.46-56","volume":"54","author":"NP Tagieva","year":"2014","unstructured":"Tagieva NP, Shakhnovich RM, Mironov VM, Ruda M. Invasive methods of detection of unstable atherosclerotic plaques in coronary arteries. Kardiologiia. 2014;54(11):46\u201356.","journal-title":"Kardiologiia"},{"issue":"7","key":"1002_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/07853890.2016.1204468","volume":"48","author":"J Pelisek","year":"2016","unstructured":"Pelisek J, Wendorff H, Wendorff C, Kuehnl A, Eckstein HH. Age-associated changes in human carotid atherosclerotic plaques. Ann Med. 2016;48(7):541\u201351.","journal-title":"Ann Med"},{"issue":"2","key":"1002_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s13239-019-00413-6","volume":"10","author":"M Zareh","year":"2019","unstructured":"Zareh M, Katul R, Mohammadi H. Mechanics of atherosclerotic plaques: effect of heart rate. Cardiovasc Eng Technol. 2019;10(2):344\u201353.","journal-title":"Cardiovasc Eng Technol"},{"issue":"4","key":"1002_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/diagnostics9040177","volume":"9","author":"E Stakhneva","year":"2019","unstructured":"Stakhneva E, Meshcheryakova I, Demidov E, Starostin K, Sadovski E, Peltek S, Voevoda M, Chernyavskii A, Volkov A, Ragino YJ. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis. Diagnostics (Basel). 2019;9(4):177.","journal-title":"Diagnostics (Basel)."},{"key":"1002_CR23","first-page":"1083","volume":"8","author":"Y Liu","year":"2013","unstructured":"Liu Y, Yang Y, Zhang CJ. A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin \u03b1v\u03b23 with magnetic probes. Int J Nanomedicine. 2013;8:1083\u201393.","journal-title":"Int J Nanomedicine"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01002-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01002-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01002-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T04:25:26Z","timestamp":1674015926000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01002-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01002-z","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"5 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study is a retrospective study. It only collects patient clinical data, does not interfere with the treatment plan of the patient, and will not bring risks to the patient\u2019s physiology. The researcher will do his best to protect the information provided by the patient from leaking personal privacy, which we applied for exemption of informed consent from Beijing Chaoyang Hospital Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}